by NMS Group | Dec 19, 2018 | 2018, News
Tokyo, 19.12.2018 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it filed a new drug application to the Ministry of Health, Labour and Welfare (MHLW) for a ROS1/TRK inhibitor entrectinib for the treatment of NTRK fusion-positive solid tumors....
by NMS Group | Dec 5, 2018 | 2018, News
Milan, 05.12.2018 The thirteenth edition of the China Awards was held under the patronage of the Ministry of Foreign Affairs, the Ministry of Economic Development and the Italian-Chinese Chamber of Commerce and in partnership with the Italian Chamber of Commerce in...
by NMS Group | Dec 3, 2018 | 2018, News
New York/London, 03.12.2018 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing...
by NMS Group | Nov 9, 2018 | 2018, News
Nerviano, 09.11.2018 NMS Group announces a signature of a Memorandum of Understanding with China Pharmaceutical University, the leading pharmacy education provider in China. Both Nerviano Medical Sciences and C.P. University promote the culture of the innovation and...
by NMS Group | Sep 7, 2018 | 2018, News
Nerviano, 07.09.2018 Nerviano Medical Sciences received a ‘Marie Skłodowska-Curie Actions Individual Fellowship’, a grant created by the European Union to support the Research and developed within the Horizon 2020 programme. The awarded grant is an acknowledgement of...
by NMS Group | Aug 2, 2018 | 2018, News
Solna, 02.08.2018 Today, Xspray Pharma reported that the first clinical trial material from NerPharMa S.r.l., Xspray’s strategic pharmaceutical manufacturing partner in Milan, has been delivered to the HyNap-Dasa clinical trial, the results of which are expected in Q3...
Welcome and Check out our new motion picture!
Recent Comments